BB Biotech (BION) Q1 2025 earnings summary

Executive summary

• Q1 2025 was marked by heightened market volatility, macro uncertainty, and new US tariffs, leading to pressure on biotech sector sentiment and performance, especially for small- and mid-caps.

• Net loss of CHF 241 mn for Q1 2025, compared to a net profit of CHF 260 mn in Q1 2024.

• Portfolio refined to 23 positions, focusing on companies above USD 1 bn in market capitalization.

• Several portfolio companies achieved regulatory and clinical milestones, including FDA approvals and positive clinical updates.

• AGM approved all proposals, including a CHF 1.80 per share dividend.

Financial highlights

• Market capitalization at period end: CHF 1,692.5 mn (down from CHF 2,368.4 mn in 2023).

• Net Asset Value at period end: CHF 1,944.5 mn (down from CHF 2,323.2 mn in 2023), declining by 10.8% in CHF and 12.3% in EUR.

• Shareholder return was -8.8% in CHF and -10.3% in EUR, with NAV declining by 10.8% in CHF and 12.3% in EUR.

• Share price closed at a 14.1% discount to NAV, consistent with year-end 2024.

• Dividend payout of CHF 1.80 per share in March 2025, continuing the 5% distribution policy.

Outlook and guidance

• Management remains cautious amid ongoing policy unpredictability, tight capital markets, and sector volatility.

• Plans to deploy cash reserves selectively to capitalize on attractive valuations, especially in small- and mid-cap biotech.

• Minimal direct impact from recent US tariff escalations; most holdings manufacture locally or focus on rare diseases.

• Focus on companies with strong balance sheets, differentiated clinical assets, and capital efficiency.

• Regulatory and trade policy shifts are being closely monitored for potential long-term industry impacts.